跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 630 条关于
“BTKi”
全部
630
临床试验
445
药物
48
机构
1
资讯
136
去年
Fixed-Duration Venetoclax Regimen Reduces Long-Term Costs in CLL Treatment
去年
Real-World Data Validates Venetoclax's Efficacy in CLL Patients After BTK Inhibitor Treatment
去年
Expert Panel Debates Treatment Strategies for High-Risk Relapsed CLL Patient with Cardiac Complications
去年
Zanubrutinib and Venetoclax Combination Shows Promise in Relapsed/Refractory CLL
3个月前
Bexobrutideg Shows High Response Rates and Manageable Safety in BTK Degrader Trial for Relapsed/Refractory CLL
去年
Study Finds No Benefit in Pausing BTK Inhibitors During COVID-19 Vaccination for CLL Patients
2年前
Ascentage Pharma's Lisaftoclax Receives FDA Clearance for Global Phase III Trial in CLL/SLL
去年
Zanubrutinib Demonstrates Durable Efficacy and Favorable Safety in CLL/SLL Treatment
去年
Iopofosine I 131 Shows Promise in Heavily Pretreated Waldenström Macroglobulinemia
6年前
Sanofi Pivots R&D Strategy, Discontinues Diabetes Research to Focus on Novel Therapeutics
第 1 页,共 14 页
上一页
下一页